We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Sionna Therapeutics Stock

Invest in or calculate the value of your shares in Sionna Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Sionna Therapeutics Stock (SITH)

Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).

About Sionna Therapeutics Stock

Founded

2018

Headquarters

Natick, MA, US

Industries

Software, Data and Analytics, Artificial Intelligence

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Sionna Therapeutics Press Mentions

Stay in the know about the latest news on Sionna Therapeutics

Sionna Therapeutics Management

Leadership team at Sionna Therapeutics

Board Member

Bruce Booth

Board Member

Edd Fleming

Locked Features

Join now and verify your accreditation status to gain access to:

  • Sionna Therapeutics current valuation
  • Sionna Therapeutics stock price
  • Available deals in Sionna Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Sionna Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Sionna Therapeutics through EquityZen funds. These investments are made available by existing Sionna Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Sionna Therapeutics stock?

Shareholders can sell their Sionna Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."